Immunosuppressive drugs committee minutes, Roma, Italy, 20 september 2021

Attending onsite: Stein Bergan (SB), Maria Shipkova (MS), Eberhart Wieland (EW), Loralie Langman (LL), Teun Van Gelder (TvG), Ofelia Noceti (ON), Kamisha Johnson-Davis (KJD), Brenda de Winter (BW), Roland Lawson, Florian Lemaitre (FL)  
(Comment: de Winter and Lawson signed in as new members.)

Attending virtually: Satohiro Masuda (SM), Tomasz Pavinzki, Michael Oellerich (MO), Olga Millan, Binu Susan Mathew, Pavel Kunicki, Mercè Brunet, Smitta Pattanaik

Stein Bergan presents the agenda of the committee. Due to the physical absence of a lot of member because of the pandemic, no formal vote on discussed points will be organized during the meeting with the exception of election of the chair and vice-chair. The final approbation of discussed points will be through mailing for everyone to get the information.

The ISD committee received an application of Brenda de Winter for joining the ISD scientific committee.

Annual general meeting

The annual general meeting has been sent to everyone for validation before being made available on the IATDMCT website.

Election of the Chair and Vice-Chair of the ISD committee

Stein Bergan’s term as the committee chair has come to an end and according to the standard process of the committee, the vice-chair becomes the new chair of the committee. Satohiro Masuda becomes now the ISD committee chair. Florian Lemaitre was elected as the new vice-chair by acclamation.

Working groups

There are three working groups within the ISD committee (Biomarkers, intracellular measurements, standardization of IS TDM). SB suggested that they will be replaced by ad hoc groups composed by members for a limited time to answer a specific question. In fact, every member is interested in each of these WG. MS thinks this WG should be changed to projects. For project completion, EW points the importance of leadership. LL points the specificity of the partnership with IFCC on standardization. The memorandum should be checked to see how it has been labeled. If it is has been stated that this was a “group”, it could be an obstacle for moving to projects.

New projects

Update of the everolimus consensus. The consensus is 5-year old and could be updated. MS comments on the analytical part of the document which should benefit from changes. A special format in which only updated information will be modified is discussed and part without changes could be skipped. FL points that very important new studies has been conducted since 2016 and should absolutely be included in the new version, particularly the TRANSFORM study.
Uptading the biomarkers consensus. EW ask whether the document should be updated as well. MO and ON support this motion.

Extension/Internationalization of the JSTDM guidelines. SM has explained that the JSTDM has a document on therapeutic drug monitoring and this is really useful to clinicians and pharmacists. MS asks if it covers all ISD. In fact it is not restricted to ISD. TvG points that our late and missed colleague, Eric Van Maarseveen, wished to translate the monograph of TDM of ISD. Brenda de Winter has worked on the document related to tacrolimus and everolimus which is intended to be proposed to hospital pharmacist. EW asks if it would be a joint document with the IATDMCT? TvG answers that it will depend on the differences between the initial and final document as it has to be validated by the directors of education and the ISD committee. If the differences are important, it won’t be a joint document. SB suggests that we get a small pilot group working on that project. JSTDM guidelines and Dutch monographs could merge into one project. It is suggested to do a test with one guideline. FL add it could be a first step before offering a joint document with clinical learning society (ESOT, ATC) on the “ideal” modalities for ISD prescribing and monitoring. KJD asks for the timeline. TvG answers it is 2 years.

Educational materials for IS pharmacology: Dirk Moes has proposed to establish a course in TDM related to transplantation. The project is still on its early stage but everyone agrees it is a good initiative. The teaching platform should be discussed in details. EW asks about the audience of this course. SB answers that it would be for our young members.

Initiative for inter-lab QC for intracellular measurements of tacrolimus. FL asks about ideas on how organize such a QC program given the need for rapid shipment. ON says she has some experience on the stability of intracellular samples and that 24h is ok but 72h is too long. SB propose a first pilot study between two centers. It could be Rennes and Rotterdam.